{"organizations": [], "uuid": "51edf58e709dafece532f10f7588027521482436", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180508.html", "section_title": "Archive News &amp; Video for Tuesday, 08 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-enanta-pharmaceuticals-reports-q2/brief-enanta-pharmaceuticals-reports-q2-earnings-per-share-0-61-idUSASC0A0KK", "country": "US", "domain_rank": 408, "title": "BRIEF-Enanta Pharmaceuticals Reports Q2 Earnings Per Share $0.61", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.662, "site_type": "news", "published": "2018-05-09T04:05:00.000+03:00", "replies_count": 0, "uuid": "51edf58e709dafece532f10f7588027521482436"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-enanta-pharmaceuticals-reports-q2/brief-enanta-pharmaceuticals-reports-q2-earnings-per-share-0-61-idUSASC0A0KK", "ord_in_thread": 0, "title": "BRIEF-Enanta Pharmaceuticals Reports Q2 Earnings Per Share $0.61", "locations": [], "entities": {"persons": [{"name": "abbvie", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-enanta pharmaceuticals reports", "sentiment": "negative"}, {"name": "enanta pharmaceuticals inc", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8 (Reuters) - Enanta Pharmaceuticals Inc:\n* ENANTA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR ITS FISCAL SECOND QUARTER ENDED MARCH 31, 2018\n* Q2 EARNINGS PER SHARE $0.61 * Q2 EARNINGS PER SHARE VIEW $0.53 — THOMSON REUTERS I/B/E/S\n* ROYALTY REVENUE FOR QUARTER INCREASED TO $44.0 MILLION DUE TO INCREASE IN ABBVIE’S MAVYRET SALES\n* QTRLY TOTAL REVENUE WAS $44.0 MILLION, COMPARED TO $9.0 MILLION Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-09T04:05:00.000+03:00", "crawled": "2018-05-09T12:39:30.008+03:00", "highlightTitle": ""}